A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer

Annals of Oncology

Volumn 23, Issue 1, 2012, Pages 72-77

  Manegold, C ^a   van Zandwijk, N ^b   Szczesna, A ^c   Zatloukal, P ^d   Au, J S K ^e   Blasinska Morawiec, M ^f   Serwatowski, P ^g   Krzakowski, M ^h   Jassem, J ⁱ   Tan, E H ^j   Benner, R J ^k   Ingrosso, A ^l   Meech, S J ^k   Readett, D ^k   Thatcher, N ^m  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF SYDNEY   (Australia)

^c Regional Lung Diseases Hospital   (Poland)

^d UNIVERSITY HOSPITAL BULOVKA   (Czech Republic)

^e QUEEN ELIZABETH HOSPITAL   (Hong Kong)

^f POLISH MOTHER S MEMORIAL HOSPITAL RESEARCH INSTITUTE   (Poland)

^g Specialistic Hospital Named After Professor A Sokolowski   (Poland)

^h INSTITUTE OF ONCOLOGY   (Poland)

ⁱ MEDICAL UNIVERSITY OF GDANSK   (Poland)

^j DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^k PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^l PFIZER INC   (United States)

^m CHRISTIE HOSPITAL   (United Kingdom)

more..

Author keywords

Cisplatin; Gemcitabine; Non small cell lung cancer; PF 3512676; TLR9 receptor

Indexed keywords

AGATOLIMOD; CISPLATIN; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BACKACHE; BLEEDING; BLISTER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CONSTIPATION; CONTROLLED STUDY; COUGHING; DEHYDRATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ERYTHEMA; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; HEMATOLOGIC DISEASE; HUMAN; INFECTION; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INJECTION SITE SWELLING; INJECTION SITE WARMTH; INSOMNIA; LEUKOPENIA; LIMB PAIN; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SURVIVAL TIME; THROMBOCYTOPENIA;

EID: 84855184648     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr030     Document Type: Article

References (23)

1. Pfister DG, Johnson DH, Azzoli CG et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004; 22: 330-353.
2. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-98.
3. Smit EF, van Meerbeeck JP, Lianes P et al. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced nonsmall-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group-EORTC 08975. J Clin Oncol 2003; 21: 3909-3917.
4. Souquet PJ, Tan EH, Rodrigues Pereira J et al. GLOB-1: a prospective randomised clinical phase III trial comparing vinorelbine-cisplatin with vinorelbine-ifosfamide-cisplatin in metastatic non-small-cell lung cancer patients. Ann Oncol 2002; 13: 1853-1861.
5. Scagliotti GV, De Marinis F, Rinaldi M et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002; 20: 4285-4291.
6. Lynch TJ, Patel T, Dreisbach L et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol 2010; 28: 911-917.
7. Pirker R, Pereira JR, Szczesna A et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009; 373: 1525-1531.
8. Reck M, von Pawel J, Zatloukal P et al. Overall survival with cisplatingemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 2010; 21: 1804-1809.
9. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-2550.
10. Krieg AM. Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides. Curr Oncol Rep 2004; 6: 88-95.
11. Krieg AM. Development of TLR9 agonists for cancer therapy. J Clin Invest 2007; 117: 1184-1194.
12. Krieg AM. Therapeutic potential of toll-like receptor 9 activation. Nat Rev Drug Discov 2006; 5: 471-484.
13. Manegold C, Gravenor D, Woytowitz D et al. Randomized phase II trial of a tolllike receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26: 3979-3986.
14. Pashenkov M, Goess G, Wagner C et al. Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. J Clin Oncol 2006; 24: 5716-5724.
15. Thompson JA, Kuzel T, Drucker BJ et al. Safety and efficacy of PF-3512676 for the treatment of stage IV renal cell carcinoma: an open-label, multicenter phase I/II study. Clin Genitourin Cancer 2009; 7: E58-E65.
16. Kim Y, Girardi M, McAuley S, Schmalbach T. Cutaneous T-cell lymphoma (CTCL) responses to a TLR9 agonist CpG immunomodulator (CPG 7909), a phase I study. J Clin Oncol 2004; 22 (Suppl): 580 (Abstr 6600).
17. Weeratna RD, Bourne LL, Sullivan SM et al. Combination of a new TLR9 agonist immunomodulator (CpG 7909) and paclitaxel for treatment of metastatic Lewis Lung Carcinoma (LLC). J Clin Oncol 2004; 22 (Suppl): 699 (Abstr 7346).
18. Hirsh V, Boyer M, Rosell R et al. Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 as first line treatment of advanced nonsmall cell lung cancer (NSCLC) [oral presentation]. J Clin Oncol 2008; 26 (Suppl): 428s (Abstr 8016).
19. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
20. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis. Common terminology criteria for adverse events v3.0 (CTCAE) 2006; http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf (14 February 2011, date last accessed).
21. Zitvogel L, Apetoh L, Ghiringhelli F et al. The anticancer immune response: indispensable for therapeutic success? J Clin Invest 2008; 118: 1991-2001.
22. US National Institutes of Health. Immunotherapy of stage III/IV melanoma patients (NCT00112242). 2005; www.clinicaltrials.gov. (5 August 2009, date last accessed).
23. US National Institutes of Health. CpG 7909/Montanide ISA 720 with or without cyclophosphamide in combination either with NY-ESO-1-derived peptides or the NY-ESO-1 protein for NY-ESO-1-expressing tumors (NCT00819806). 2009; www.clinicaltrials.gov. (5 August 2009, date last accessed).